ABSTRACT & COMMENTARY

Ablation vs. Drug Therapy for Atrial Fibrillation, Revisited

Name: Relias Media
Price range: $

February 28, 2023

A three-year follow-up of EARLY-AF, a study of relatively young and healthy patients with recent atrial fibrillation, showed cryoablation remains superior to drug therapy for preventing the development of persistent atrial fibrillation.

Issue Date: February 28, 2023

Table of Contents

Dr. Stephen Brunton, physician editor, reports he is on the speakers bureau for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi; is a retained consultant for AstraZeneca, Novo Nordisk, and Sanofi; and is a stockholder with Paracrine. The relevant financial relationships listed have been mitigated. None of the remaining planners or authors for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements